SOVETNIK BOLYuSA": EFFEKTIVNOE I BEZOPASNOE UPRAVLENIE POSTPRANDIAL'NOY GLIKEMIEY U PATsIENTOV NA POMPOVOY INSULINOTERAPII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Postprandial blood glucose level is an important «target» for the multifactorial management of diabetes mellitus (DM). However, many patients on insulin do not achieve target postprandial blood glucose levels due to an incorrect calculation of doses. For the facilitation of this task, most of the modern insulin pumps have a predefined function of calculation of prandial insulin dose - “bolus advisor". The present review is devoted to the evaluation of clinical efficacy and safety of such programs.

Full Text

Restricted Access

References

  1. The Diabetes Control and Complications Trial Study Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.
  2. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643-53.
  3. Group UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53.
  4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008;359(15):1577-89.
  5. Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963-72.
  6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28(2):103-17.
  7. Shiraiwa T, Kaneto H, Miyatsuka T, et al. Post prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 2005;336(1):339-45.
  8. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164(19):2147-55.
  9. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25(1):10-6.
  10. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007.
  11. Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased carotid intimamedia thickness in non-diabetic individuals. Atherosclerosis 1999;144(1):229-35.
  12. Halimi S, Raskin P, Liebl A, et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005;27(Suppl. 2):57-74.
  13. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20(3):145-52.
  14. Schernthaner G, Kopp HP, Ristic S, et al. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004;36(3):188-93.
  15. Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabet Med 2006;23(7):743-49.
  16. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24(10):1734-38. технических и функциональных особенностях инсулиновых помп, алгоритмах оценки и коррекции проводимой терапии. В связи с этим обучение пациентов самостоятельному управлению своим заболеванием должно по-прежнему оставаться базовым компонентом комплексного и многофакторного подхода к лечению СД. Только в этом случае можно добиться эффективности внедрения помповой инсулинотерапии в клиническую практику и системы долгосрочного управления СД.
  17. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49(5):846-54.
  18. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c). Diabetes Care 2003;26(3):881-85.
  19. Bastyr EJ, III, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23(9):1236-41.
  20. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-86.
  21. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405.
  22. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28(11):2626-32.
  23. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91(3):813-19.
  24. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53(3):701-10.
  25. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97(17):1695-701.
  26. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34(1): 146-54.
  27. Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67(2):235-40.
  28. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283(19):2552-58.
  29. Larsson SC, Bergkvist L, Wolk A. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am J Clin Nutr 2006;84(5):1171-76.
  30. Michaud DS, Liu S, Giovannucci E, et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002;94(17):1293-300.
  31. Michaud DS, Fuchs CS, Liu S, et al. Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2005;14(1):138-47.
  32. Lajous M, Willett W, Lazcano-Ponce E, et al. Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control 2005;16(10):1165-69.
  33. National Diabetes Audit Executive Summary 2008-2009. Key findings about the quality of care for people with diabetes in England and Wales. England: The NHS Information Centre; 2010.
  34. Di Battista AM, Hart TA, Greco L, Gloizer J. Type diabetes among adolescents: reduced diabetes self-care caused by social fear and fear of hypoglycemia. Diabetes Educ 2009;35(3):465-75.
  35. Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350(9090):1505-10.
  36. Smith CB, Choudhary P, Pernet A, et al. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009;32(7): 1196-98.
  37. Ahola AJ, Makimattila S, Saraheimo M, et al. Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately. J Diabetes 2010;2(3):194-202.
  38. de Weerdt I, Visser A, Kok G, van der Veen E. Randomized controlled evaluation of an education programme for insulin treated patients with diabetes: effects on psychosocial variables. Patient Educ Counsel 1989;14:191-215.
  39. de Weerdt I, Visser A, Kok G, et al. Randomized controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life, and costs of therapy. Diabet Med 1991;8:338-45.
  40. Bloomgarden Z, Karmally W, Metzger M, et al. Randomized, controlled trial of diabetic patient education: improved knowledge without improved metabolic status. Diabetes Care 1987;10:263-72.
  41. Cavanaugh K, Huizinga MM, Wallston KA, et al. Association of numeracy and diabetes control. Ann Intern Med 2008;148(10):737-46.
  42. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25(3):593-98.
  43. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18(Suppl. 1):14-20.
  44. Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Hyperglycaemia, hypoglycaemia, and blood glucose control in diabetes: symptom perceptions and treatment strategies. Diabet Med 1992;9(2):120-25.
  45. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patien Educ Couns 2007;68(1):10-5.
  46. Cukierman-Yaffe T, Konvalina N, Cohen O. Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes. Diabetes Res Clin Pract 2011;92(1):69-73.
  47. Klupa T, Benbenek-Klupa T, Malecki M, et al. Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res 2008;36(5):1112-16.
  48. Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 2003;5(3):365-69.
  49. Barnard KD, Parkin CG, Young A, Ashraf M. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidene in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. J Diab Sci Tech 2012;6(1): 144-49.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies